Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer

Just under 100 non-small cell lung cancer patients in England will be eligible for the drug

- PMLiVE

British Medical Association GP committee votes to phase out physician associates

The majority of members voted that the role is “fundamentally unsafe” in general practice

- PMLiVE

Influencing the future of healthcare communications

By Claire Knapp and Tapas Mukherjee

- PMLiVE

Innovative Trials named a finalist at the PME Award

Patient recruitment and retention company, Innovative Trials, was shortlisted as a finalist in the PME Award for its collaboration with US non-profit Oliver Patch Project to improve patient outcomes.

Innovative Trials

- PMLiVE

AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA

More than ten million people worldwide are living with the neurological disorder

- PMLiVE

GSK’s investigational antibiotic granted FDA priority review for urinary tract infections

Gepotidacin could be the first in a new class of oral antibiotics for uncomplicated UTIs in over 20 years

- PMLiVE

Stirred becomes first UK health comms agency to achieve EcoVadis Platinum Medal

The rating places Stirred in the top 1% of companies globally in business sustainability assessments

- PMLiVE

Precision, planning and creativity for launch excellence in a volatile sector

The dynamic launch excellence environment has many challenges but is full of opportunity

- PMLiVE

Sex, Gender, and the Brain: The Women’s Brain Foundation and Medscape Education Announce Groundbreaking Learning Centre

LONDON--(BUSINESS WIRE)--The Women’s Brain Foundation (WBF), the global pioneer that has advanced the inclusion of sex- and gender-based evidence-generation in all research, drug development, and healthcare since 2017; and Medscape...

Medscape Education

- PMLiVE

AstraZeneca receives MHRA approval for Wainzua in rare nerve disease ATTRv-PN

The therapy is designed to reduce the effects of the disease by lowering the production of TTR protein

- PMLiVE

Sanofi and Orano Med partner to advance radioligand therapies for rare cancers

The companies will invest in a new entity that will operate under the Orano Med brand

- PMLiVE

Amgen shares positive late-stage results for Uplizna in generalised myasthenia gravis

The company said it is planning to file for US approval of the drug in this indication

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links